Healx

Our co-founder and CEO Tim Guilliams is looking forward to participating in a panel discussion on how #AI is reshaping healthcare at Balderton Capital’s “From code to cure: AI's reshaping of drug discovery” event in London. Tim will highlight how Healx is leveraging generative AI to build a pipeline of patient-inspired treatments for #rarediseases. Learn more about the private event here: https://lnkd.in/eZAe2BB8

We are pleased to announce the appointment of Jonathan Milner, Ph.D.,  as the new non-executive chairman of the board, effective immediately. Dr. Milner is a distinguished entrepreneur and an influential figure in the UK life sciences and #biotech industry with a strong track record of fostering innovation. In addition to serving on several boards, he has contributed his expertise to numerous startups and established organisations, and we are grateful to have him at Healx. This transition comes as current chairman and co-founder David Brown, Ph.D., begins a secondment to pursue academic research at Trinity College, Cambridge University. Dr. Brown will remain an active member of the Healx board, continuing to contribute and support Tim Guilliams, Ph.D., co-founder and CEO of Healx, and Dr. Milner in advancing Healx’s mission. Read more about this update here: https://lnkd.in/eQf2TvQx

We're extending our sincerest congratulations to Healx Co-founder David Brown, Ph.D., for being awarded the 2024 OBN (UK) Ltd Awards Special Recognition Award. Over the span of 50 years, and in addition to his leadership at Healx, Dr. Brown has worked with leading pharmaceutical companies and is responsible for many tremendous achievements, including the co-invention of Viagra during his time at Pfizer. His many accomplishments include improving access to medicines in less advantaged countries, sponsoring a global challenge to find innovative treatments for sepsis, and becoming an entrepreneur coach at Cambridge University Business School. We're grateful to work closely with Dr. Brown as he helps guide our mission of creating generative AI-powered, patient-inspired treatments for people living with #rarediseases. https://lnkd.in/eyaW3XNS

We are proud to partner with the Children's Tumor Foundation (CTF) since 2020 to combine our cutting-edge #AI platform and drug discovery expertise with CTF’s preclinical and clinical research and patient knowledge in identifying novel treatments for #rarediseases including Neurofibromatosis Type 1 (#NF1). In the video below, hear from our Head of Neurofibromatosis Therapy Development Simone Manso and CEO/President of CTF Dr. Annette Bakker as they discuss the importance of patient-centric research and how the partnership is beneficial in gaining patients' perspectives.

Important collaboration update: We just announced that we will be analyzing data from a proprietary Sanofi compound using Healnet, our AI-driven #drugdiscovery platform, in order to identify new disease indications for this asset. This is a significant third-party endorsement of the power of our platform and one example of the ways we aim to leverage our platform and #AI capabilities as we work toward our mission to bring new treatments to patients with rare diseases. Read More: https://lnkd.in/eVuKf6Kp

At Healx, we believe every rare disease patient deserves a treatment. Our Senior Director, Drug Discovery Richard Davenport FRSC and Head of Operations, People & Tech Nick Street will be participating in the OBN (UK) Ltd Ltd BioTuesday session next week in London. They will contribute to a conversation about the funding landscape and regulatory challenges within the #raredisease space and hear first-hand from a rare disease patient group. Read more about the event here: https://lnkd.in/gbv-ahjK

Growth is a journey fueled by curiosity, collaboration, and mutual respect for one another. Our team is dedicated to learning, sharing knowledge, and amplifying every voice to drive meaningful impact for the #raredisease community. By embracing diverse perspectives and fostering an environment of trust, we empower one another to continuously evolve and excel, leading to better outcomes. Learn more about our company values here: https://healx.ai/about/

Exciting Progress in Rare Disease Treatment at Healx! Proud to share that our lead program, HLX-1502, has received FastTrack designation from the FDA, bringing us one step closer to delivering a breakthrough treatment for neurofibromatosis type 1 (NF1). This designation underscores the urgent need for new therapeutic options in NF1 and accelerates our path to making a real impact for patients and their families. Explore our latest blog to learn more about HLX-1502, what FastTrack means for our team and the NF1 community, and the next steps in our journey. Read more on our website: https://lnkd.in/gjMayGgP #Healx #RareDisease #NF1 #FastTrack #Biotech #FDA

In a recent Forbes article, our CEO, Tim Guilliams, shared insights on the challenges founders face and the importance of resilience. Building a company, especially one like Healx focused on #rarediseases, requires both innovation and personal wellbeing. At Healx, we recognise that founder health is crucial to sustained success. Supporting a culture that values mental and physical resilience benefits not only each individual at our company but our entire mission. Read the full article here: https://lnkd.in/gESqgxty 

We recently hosted our quarterly team days in Cambridge, UK! Team days are a great opportunity for the full Healx team to get together and connect on our mission to transform the lives of individuals living with #rarediseases. During three action-packed days, we participated in a variety of workshops, shared our latest learnings and heard from our board members Jonathan Milner and our co-founder and chairman Dr. David Brown in a fireside chat. We're thankful for moments like these to collaborate under one roof, plan toward near-term goals, and celebrate our recent achievements together.